Kiora Pharmaceuticals Inc. (KPRX)

Nov 8, 2024, 7:00 AM EST - 2 months ago

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Oct 29, 2024, 6:45 AM EDT - 2 months ago

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Sep 25, 2024, 9:55 AM EDT - 4 months ago

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Sep 9, 2024, 4:55 PM EDT - 4 months ago

Bonds still bouncing along

CPLS EYEG HYFI JPST TLT USHY YEAR

Aug 9, 2024, 7:00 AM EDT - 5 months ago

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

Jul 30, 2024, 6:45 AM EDT - 6 months ago

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies

Jul 10, 2024, 7:00 AM EDT - 6 months ago

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

Jul 1, 2024, 6:54 AM EDT - 7 months ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

DARE

Jun 25, 2024, 6:45 AM EDT - 7 months ago

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

May 10, 2024, 7:00 AM EDT - 9 months ago

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

May 8, 2024, 7:00 AM EDT - 9 months ago

Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference

May 6, 2024, 7:00 AM EDT - 9 months ago

Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa

Apr 11, 2024, 7:00 AM EDT - 10 months ago

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study

Apr 5, 2024, 7:00 AM EDT - 10 months ago

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Mar 28, 2024, 6:45 AM EDT - 10 months ago

Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Mar 25, 2024, 7:00 AM EDT - 10 months ago

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Mar 8, 2024, 7:00 AM EST - 11 months ago

Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

Jan 31, 2024, 6:40 PM EST - 1 year ago

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

Jan 31, 2024, 5:15 PM EST - 1 year ago

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini

Dec 13, 2023, 7:30 AM EST - 1 year ago

AllianceBernstein Launches Five New Active ETFs

AB BUFC CPLS EYEG TAFL TAFM

Nov 9, 2023, 7:18 AM EST - 1 year ago

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

Nov 4, 2023, 12:15 PM EDT - 1 year ago

AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 3, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

Sep 21, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Sep 18, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

Sep 14, 2023, 7:01 AM EDT - 1 year ago

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

Sep 1, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27

Aug 29, 2023, 1:43 PM EDT - 1 year ago

Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases

Aug 23, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis

Aug 22, 2023, 1:06 PM EDT - 1 year ago

Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program

Aug 16, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Aug 8, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress

Aug 3, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment

Aug 1, 2023, 7:00 AM EDT - 1 year ago

Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors

Jul 5, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease

Jun 15, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201

Jun 6, 2023, 4:30 PM EDT - 1 year ago

Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Jun 2, 2023, 8:30 AM EDT - 1 year ago

Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering

May 9, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments

May 1, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting

Apr 27, 2023, 2:55 PM EDT - 1 year ago

Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind

Apr 26, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects

Apr 21, 2023, 7:00 AM EDT - 1 year ago

Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

Apr 17, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases

Mar 30, 2023, 7:00 AM EDT - 1 year ago

Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting

Mar 23, 2023, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress

Mar 10, 2023, 7:00 AM EST - 2 years ago

Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting

Feb 7, 2023, 8:00 AM EST - 2 years ago

Kiora's stock rallies as eye drop treatment moves into mid-stage clinical trial